ATC codes: J01XX08
Vancomycin resistant Enterococcus ICD11 code: MG51.20
Medicine type
Chemical agent
Antibiotic groups
List type
Complementary (EML)
Additional notes
The square box applies only to the listing of linezolid on the EML
Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid > dispersible tablet: 150 mg (EMLc)
Oral > Solid > tablet: 600 mg (EML)
EML status history
First added in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Also recommended for children
Therapeutic alternatives
tedizolid (ATC codes: J01XX11)
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Summary of evidence and Expert Committee recommendations
The Committee recommended inclusion of tedizolid phosphate on the complementary list of the EML as a Reserve group antibiotic for the treatment of infections caused or suspected to be caused by multidrug-resistant Gram-positive pathogens (methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci), as an alternative to linezolid under a square box listing. The recommendation was based on evidence indicating that tedizolid is non-inferior to linezolid for the treatment of acute bacterial skin and skin structure infections, with a lower incidence of adverse events. However, the Committee observed that tedizolid phosphate is currently less widely available and considerably more expensive than linezolid. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of linezolid 150 mg dispersible tablets to the EMLc, the removal of linezolid 400 mg tablets from the EML and EMLc, and the removal of linezolid 600 mg tablets from the EMLc.